Trial · NCT02081534

Dose Finding Study to Treat High Phosphate Levels in the Blood.

NCT02081534, Phase 2, Completed, Ardelyx; results first posted 2020-09-14

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Dose Finding Study to Treat High Phosphate Levels in the Blood. Trials, record NCT02081534. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02081534

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Dose Finding Study to Treat High Phosphate Levels in the Blood.
NCT number: NCT02081534
Status: Completed
Phases: Phase 2
Enrollment: 162 participants, actual
Lead sponsor: Ardelyx
Conditions: Hyperphosphatemia
Interventions: AZD1722, Placebo
First posted: 2014-03-07
Last updated: 2020-09-14
Results first posted: 2020-09-14

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Serum Phosphate Levels	End of wash out (pre randomization value) to end of treatment (Day 29)	Change in serum phosphate levels from the end of wash out (pre randomization value) to end of treatment
Secondary	Change From Baseline in Calcium x Phosphorus Product	End of wash out (pre randomization value) to end of treatment (Day 29)	Change from baseline (end of wash out) in calcium x phosphorus product

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Serum Phosphate Levels	End of wash out (pre randomization value) to end of treatment (Day 29)	two patients in the 30 mg bid group are not included in the analysis since they had no post randomization serum phosphorus measurements	mg/dL	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Calcium x Phosphorus Product	End of wash out (pre randomization value) to end of treatment (Day 29)	The number of patients analyzed are less than the randomized number since the data to accomplish the analysis was not available.	mg/dL * mg/dL	MEAN

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Serum Phosphate Levels	1 mg Bid	-.47	Standard Deviation 1.553	mg/dL
Change in Serum Phosphate Levels	3 mg Bid	-1.18	Standard Deviation 1.391	mg/dL
Change in Serum Phosphate Levels	10 mg Bid	-1.7	Standard Deviation 2.018	mg/dL
Change in Serum Phosphate Levels	30 mg Bid	-1.98	Standard Deviation 2.007	mg/dL
Change in Serum Phosphate Levels	3 mg od	-.56	Standard Deviation 1.763	mg/dL
Change in Serum Phosphate Levels	30 mg od	-1.11	Standard Deviation 1.469	mg/dL
Change in Serum Phosphate Levels	Placebo	-.54	Standard Deviation 1.802	mg/dL
Change From Baseline in Calcium x Phosphorus Product	1 mg Bid	-5.16	Standard Deviation 9.75	mg/dL * mg/dL
Change From Baseline in Calcium x Phosphorus Product	3 mg Bid	-12.02	Standard Deviation 14.02	mg/dL * mg/dL
Change From Baseline in Calcium x Phosphorus Product	10 mg Bid	-12.44	Standard Deviation 15.94	mg/dL * mg/dL

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow21

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	1 mg Bid	23
Overall Study	STARTED	3 mg Bid	21
Overall Study	STARTED	10 mg Bid	23
Overall Study	STARTED	30 mg Bid	26
Overall Study	STARTED	3 mg od	22
Overall Study	STARTED	30 mg od	21
Overall Study	STARTED	Placebo	26
Overall Study	COMPLETED	1 mg Bid	18
Overall Study	COMPLETED	3 mg Bid	13
Overall Study	COMPLETED	10 mg Bid	19

1 to 10 of 21Source ClinicalTrials.gov

See all 21 participant flow

Adverse events98

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Diarrhea	Gastrointestinal disorders	1 mg Bid	6	23	6
other	Diarrhea	Gastrointestinal disorders	3 mg Bid	6	21	6
other	Diarrhea	Gastrointestinal disorders	10 mg Bid	11	23	11
other	Diarrhea	Gastrointestinal disorders	30 mg Bid	17	26	17
other	Diarrhea	Gastrointestinal disorders	3 mg od	4	22	4
other	Diarrhea	Gastrointestinal disorders	30 mg od	11	21	11
other	Diarrhea	Gastrointestinal disorders	Placebo	3	26	3
serious	Chest pain	Cardiac disorders	1 mg Bid	1	23	1
serious	Chest pain	Cardiac disorders	3 mg Bid	0	21	0
serious	Chest pain	Cardiac disorders	10 mg Bid	0	23	0

1 to 10 of 98Source ClinicalTrials.gov

See all 98 adverse events

Adverse event totals21

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	1 mg Bid	1	23
Total, all-cause mortality	3 mg Bid	0	21
Total, all-cause mortality	10 mg Bid	0	23
Total, all-cause mortality	30 mg Bid	0	26
Total, all-cause mortality	3 mg od	0	22
Total, all-cause mortality	30 mg od	0	21
Total, all-cause mortality	Placebo	0	26
Total, other adverse events	1 mg Bid	6	23
Total, other adverse events	3 mg Bid	6	21
Total, other adverse events	10 mg Bid	11	23

1 to 10 of 21Source ClinicalTrials.gov

See all 21 adverse event totals

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
29617976	DERIVED	PubMed
38323855	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02081534

GET https://conductscience.org/api/trials/v1/NCT02081534/flow?page=2

API reference For AI assistants